New Generation Hepatitis Therapy: PEG Interferon A2 (Pegasus) Shows Superior Efficacy in Treating Hepatitis B

Hepatitis B is a serious liver infection affecting over 2 billion people globally. Despite an effective vaccine, many suffer from chronic infection. A new therapy, Pegasus, shows superior efficacy compared to conventional interferon, attributed to its unique pharmacokinetic profile. Pegasus maintains stable drug concentrations, enhancing immune response and inhibiting the virus. Developed by Roche, it is easy to administer with no dose adjustments. Ongoing studies aim to explore longer treatment durations for better outcomes.

What new insight or understanding did you gain from this video?